Cargando…

A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia

BACKGROUND AND AIMS: Pharmaceutical therapy for NASH is associated with lipid modulation, but the consensus on drug treatment is limited and lacks comparative analysis of effectiveness. A network meta-analysis was conducted to compare NASH drug classes in lipid modulation. METHODS: Online databases...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Jieling, Ng, Cheng-Han, Chin, Yip-Han, Tan, Darren Jun Hao, Lim, Wen-Hui, Lim, Grace, Quek, Jingxuan, Tang, Ansel Shao Pin, Chan, Kai-En, Soong, Rou-Yi, Chew, Nicholas, Tay, Benjamin, Huang, Daniel Q., Tamaki, Nobuharu, Foo, Roger, Chan, Mark Y., Noureddin, Mazen, Siddiqui, Mohammad Shadab, Sanyal, Arun J., Muthiah, Mark D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	XIA & HE Publishing Inc. 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634784/ https://www.ncbi.nlm.nih.gov/pubmed/36381095 http://dx.doi.org/10.14218/JCTH.2022.00095

Ejemplares similares

Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality
por: Ng, Cheng Han, et al.
Publicado: (2022)

Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
por: Noureddin, Mazen, et al.
Publicado: (2019)

Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality
por: Ng, Cheng Han, et al.
Publicado: (2022)

A poor perspective of self weight significantly increases adverse outcomes in non-alcoholic fatty liver disease (NAFLD)
por: Fu, Clarissa Elysia, et al.
Publicado: (2022)

Foregut bypass vs. restrictive bariatric procedures for nonalcoholic fatty liver disease: a meta-analysis of 3,355 individuals
por: Lim, Wen Hui, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals
por: Tang, Ansel Shao Pin, et al.
Publicado: (2022)

DEXA Scan Body Fat Mass Distribution in Obese and Non-Obese Individuals and Risk of NAFLD—Analysis of 10,865 Individuals
por: Tan, Caitlyn, et al.
Publicado: (2022)

The placebo response rate and nocebo events in obesity pharmacological trials. A systematic review and meta-analysis
por: Chin, Yip Han, et al.
Publicado: (2022)

Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis
por: Tan, Darren Jun Hao, et al.
Publicado: (2022)

The Association of Plant-Based Diet With Cardiovascular Disease and Mortality: A Meta-Analysis and Systematic Review of Prospect Cohort Studies
por: Quek, Jingxuan, et al.
Publicado: (2021)

Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals
por: Ng, Cheng Han, et al.
Publicado: (2023)

Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?
por: Noureddin, Nabil, et al.
Publicado: (2020)

Global prevalence of depression and anxiety in patients with hepatocellular carcinoma: Systematic review and meta-analysis
por: Tan, Darren Jun Hao, et al.
Publicado: (2022)

Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
por: Eskridge, Wayne, et al.
Publicado: (2023)

Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials
por: Tan, Darren Jun Hao, et al.
Publicado: (2023)

Historical Changes in Weight Classes and the Influence of NAFLD Prevalence: A Population Analysis of 34,486 Individuals
por: Nah, Benjamin Kai Yi, et al.
Publicado: (2022)

868: PREVENTING HEPATCELLULAR CARCINOMA WITH TENOFOVIR VS ENTECAVIR: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF PROPENSITY SCORE MATCHED STUDIES
por: Tan, Darren J., et al.
Publicado: (2022)

Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge
por: Steggerda, Justin A, et al.
Publicado: (2020)

Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis
por: Tan, Darren Jun Hao, et al.
Publicado: (2022)

Predictive and Prognostic Roles of Gut Microbial Variation in Liver Transplant
por: Wong, Hon Jen, et al.
Publicado: (2022)

Can glucose‐lowering medications improve outcomes in non‐diabetic heart failure patients? A Bayesian network meta‐analysis
por: Yeong, Trevor, et al.
Publicado: (2022)

Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know
por: Barritt, A. Sidney, et al.
Publicado: (2022)

The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease
por: Ng, Cheng Han, et al.
Publicado: (2022)

A network meta-analysis of 12,116 individuals from randomized controlled trials in the treatment of depression after acute coronary syndrome
por: Lim, Grace En Hui, et al.
Publicado: (2022)

Is Fatty Liver Associated With Depression? A Meta-Analysis and Systematic Review on the Prevalence, Risk Factors, and Outcomes of Depression and Non-alcoholic Fatty Liver Disease
por: Xiao, Jieling, et al.
Publicado: (2021)

Review article: the impact of liver‐directed therapies on the atherogenic risk profile in non‐alcoholic steatohepatitis
por: Connelly, Margery A., et al.
Publicado: (2020)

A qualitative systematic review of anonymous/unspecified living kidney and liver donors’ perspectives
por: Lim, Wen Hui, et al.
Publicado: (2022)

The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases
por: Chew, Nicholas W.S., et al.
Publicado: (2022)

Role of aramchol in steatohepatitis and fibrosis in mice
por: Iruarrizaga‐Lejarreta, Marta, et al.
Publicado: (2017)

Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis
por: Jacobson, Ira M., et al.
Publicado: (2022)

Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis
por: Noureddin, Mazen, et al.
Publicado: (2023)

High-fat but not sucrose intake is essential for induction of dyslipidemia and non-alcoholic steatohepatitis in guinea pigs
por: Ipsen, David Højland, et al.
Publicado: (2016)

Associations of Fatty Liver Disease with Hypertension, Diabetes, and Dyslipidemia: Comparison between Alcoholic and Nonalcoholic Steatohepatitis
por: Toshikuni, Nobuyuki, et al.
Publicado: (2017)

Recent advances in understanding/management of non-alcoholic steatohepatitis
por: Pacana, Tommy, et al.
Publicado: (2015)

Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis
por: Albhaisi, Somaya, et al.
Publicado: (2021)

Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2020)

Harnessing Muscle–Liver Crosstalk to Treat Nonalcoholic Steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

General Public’s knowledge, awareness, and perception of Cardiometabolic diseases: data from a Singapore study population
por: Anand, Vickram Vijay, et al.
Publicado: (2023)

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
por: Tokushige, Katsutoshi, et al.
Publicado: (2021)

Role of PAI-1 in hepatic steatosis and dyslipidemia
por: Levine, Joshua A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rtil6gmgt2u8f7focr7h3usn12